The Premier Meeting Across all Stakeholders in Immuno-Oncology
Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, addressing key aspects from all facets of IO including:
Discovery / Preclinical Science
Biomarkers / Diagnostics
Trends in the Field
Dr Axel Hoos, GSK and Dr James Gulley, NCI, together led the design of the 4th annual Immuno-Oncology 360° program to include 70 speakers and over 60 talks. We are delighted to announce that Dr Andrew Baum is confirmed as the investor relations plenary keynote.
Immuno-Oncology 360° provides the most up-to-date research, data and progress to help IO stakeholders:
Who Should Attend
The program is designed for large pharma, mid-sized biopharma, biotechs and investors seeking to accelerate clinical trials in the emerging immuno oncology space.
Showcase your company in front of this prestigious audience.
Benefits of being a part of the event
Quick-fire & Biotechnology Showcase
Novel biotechnology companies that are developing immunotherapy assets have the opportunity to showcase their data in front of large pharma and investors who are seeking new innovative sources to contribute to their pipelines to advance the treatment of cancer. Service providers have an opportunity to showcase how they are able to collaborate and partner with BioPahrm companies. The showcase package includes branding and networking benefits as follows:
|AIC2015 - Autumn Immunology Conference||Chicago||Illinois||-||-||Nov 20, 2015|
|AIC2016 - Autumn Immunology Conference||Chicago||Illinois||-||-||Nov 18, 2016|
|24th Annual Pennsylvania Immunization Conference 2018||Harrisburg||Pennsylvania||80||-||Aug 16, 2018|
|Entomology 2018 - Entomological Society of America||Vancouver||British Columbia||3,200||60||Nov 11, 2018|
|Immuno-Oncology 360||New York||New York||500e||30||Feb 6, 2019|